PROCEPT BioRobotics Corp. PRCT

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced that Rick McDowell has joined the company as Vice President, Sales. In this role, Rick will report to Chris Marrus, Executive Vice President, and will lead THINK Surgical's national sales organization, driving market strategy and growth as the company continues to scale its commercial operations.

SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings at the upcoming Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15. To view the presentation or schedule a meeting with management, please reach out to your Baird

Price targets for PROCEPT BioRobotics have been reset closer to its revised fair value, with many now clustered in the low to mid US$20s instead of around US$30. Analysts linking these lower targets to slower procedure trends, competition risk and the overhang from recent legal actions have shifted several ratings to Hold, Neutral or Market Perform. As you read on, you will see how this evolving analyst narrative may shape how you track PROCEPT BioRobotics from here. Analyst Price Targets...

Moby summary of PROCEPT BioRobotics Corporation's Q2 2026 earnings call

Despite record system ASPs and robust new account performance, the company lowers full-year procedure guidance as legacy AquaBeam sites underperform.

SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2026. "This was an important quarter for PROCEPT as we continued to strengthen the foundation of our business for long-term growth," said Larry Wood, Chief Executive Officer. "We delivered 19% rev

In the past week, multiple securities law firms, including Robbins Geller Rudman & Dowd LLP and Rosen Law Firm, announced class action lawsuits against PROCEPT BioRobotics, alleging undisclosed discounting practices that inflated reported U.S. handpiece sales and conflicted with prior guidance between February 2024 and February 2026. The lawsuits focus on claims that PROCEPT’s bulk-order discount program pulled sales forward, left more than 10,000 excess handpiece units in the field, and...

The acquisition transforms Processa’s pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor TakeawaysProcessa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline.

PROCEPT BioRobotics (PRCT) is back in focus after a class action lawsuit filed in federal court alleged the company used undisclosed discount programs that inflated sales metrics and contributed to excess inventory. See our latest analysis for PROCEPT BioRobotics. At a latest share price of $17.69, PROCEPT BioRobotics has seen a 1-day share price return of 5.99%, although the 30-day share price return is down 21.59% and the year-to-date share price return is down 42.49%. The 1-year total...

SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the

With significant hedge fund interest and strong upside, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the most promising robotics stocks. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is building a clinical case for Aquablation that could redefine its addressable market, with two major prostate cancer study milestones drawing fresh analyst attention to the stock. On May 28, 2026, […]

NEW YORK, June 29, 2026--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors.

PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is one of the 10 best robotics and automation stocks to invest in. On May 28, PROCEPT BioRobotics Corp. (NASDAQ:PRCT) disclosed two significant accomplishments in its WATER IV prostate cancer clinical program. Firstly, the company received FDA approval for an Investigational Device Exemption for the second randomized study to evaluate Aquablation […]